Trials / Terminated
TerminatedNCT02837757
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. The objective of this study is to investigated the influence of everolimus immune modulation on antitumor efficacy .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biological samples | blood and tumor tissue samples |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2019-12-18
- Completion
- 2019-12-18
- First posted
- 2016-07-20
- Last updated
- 2022-05-16
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02837757. Inclusion in this directory is not an endorsement.